17

17 Publications Verification

Synonyms: Huazhongilexone

Category:

Plants Other Families Extract Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Flavonones Phenols Polyphenols Disease Research Fields Inflammation/Immunology

Target:

Melanocortin Receptor TRP Channel

Eriodictyol ((±)-Huazhongilexone; Dihydroluteolin) is an orally active TRPV1 receptor antagonist (IC₅₀=44-47 nM, rTRPV1) with antioxidant and anti-inflammatory activities. Eriodictyol effectively inhibits lipid peroxidation and the release of proinflammatory cytokines by specifically antagonizing the TRPV1 receptor and activating the Nrf2 signaling pathway. Eriodictyol reduces the levels of ICAM-1, VEGF, eNOS and TNF-α in the retina and maintains the integrity of the blood-retinal barrier. Eriodictyol alleviates oxidative stress-induced apoptosis and hyperalgesia, enhances the activity and cytotoxicity of immune cells (such as B lymphocytes, NK cells and macrophages), and increases the levels of antioxidant enzymes simultaneously. Eriodictyol can be used in the research of diabetic retinopathy, acute lung injury and various pain-related diseases ^[1] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

12

Lifitegrast

12 Cited Publications

Cat. No.: HY-19344

CAS No.: 1025967-78-5

Synonyms: SAR 1118; SHP-606

Target:

Integrin

Research Areas:

Inflammation/Immunology

Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease ^[1].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

12

Lifitegrast sodium

12 Cited Publications

Cat. No.: HY-19344A

CAS No.: 1119276-80-0

Synonyms: SAR 1118 sodium; SHP-606 sodium

Target:

Integrin

Research Areas:

Inflammation/Immunology

Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease ^[1].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

Leukadherin-1

6 Cited Publications

Cat. No.: HY-15701

CAS No.: 344897-95-6

Purity: ≥98.0%

Target:

Integrin Complement System

Research Areas:

Inflammation/Immunology

Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC₅₀ of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling ^[1] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

6

AF12198

6 Cited Publications

Cat. No.: HY-P1110

CAS No.: 185413-30-3

Target:

Interleukin Related

Research Areas:

Inflammation/Immunology

AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC₅₀=8 nM) but not the human type II receptor (IC₅₀=6.7 µM) or the murine type I receptor (IC₅₀>200 µM). AF12198 inhibits IL-1-induced IL-8 production (IC₅₀=25 nM) and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression (IC₅₀=9 nM) in vitro. AF12198 has anti-inflammatory activities and blocks responses to IL-1 in vivo ^[1].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

A-205804

5 Cited Publications

Cat. No.: HY-100226

CAS No.: 251992-66-2

Purity: 98.25%

Target:

Integrin

Research Areas:

Inflammation/Immunology

A-205804 is an orally bioavailable, potent and selective lead inhibitor of E-selectin and ICAM-1 expression, with an IC₅₀ of 20 nM and 25 nM for E-selectin and ICAM-1, respectively. A-205804 can be used in the research of chronic inflammatory diseases ^[1].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Natalizumab (Anti-CD49d)

5 Cited Publications

Cat. No.: HY-108831A

CAS No.: 189261-10-7

Purity: 98.72%

Synonyms: AN100226; BG00002

Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses ^[1] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Natalizumab

5 Cited Publications

Cat. No.: HY-108831

CAS No.: 189261-10-7

Purity: 99.10%

Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 ⁺ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses ^[1] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

BIRT 377

5 Cited Publications

Cat. No.: HY-110117

CAS No.: 213211-10-0

Purity: 99.82%

Target:

Integrin Interleukin Related

Research Areas:

Inflammation/Immunology

BIRT 377 is a potent amd orally bioavailable inhibitor of the interaction between intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1). BIRT 377 also inhibits the production of IL-2 in vivo. BIRT 377 can be used for researching inflammatory and immune disorders ^[1].

Compare

loading...